前瞻性、随机、多中心、双盲临床试验:波士顿人工角膜载体组织的角膜交联
这项前瞻性、双盲、随机、多中心临床试验纳入68例计划接受波士顿人工角膜(BKPro)植入的成人受试者,1:1随机接受交联(CXL)或非交联(non-CXL)供体角膜载体。结果显示,CXL组与非CXL组在装置取出时间上无差异(P=.910),12个月保留率CXL组94% vs non-CXL组82%(P=.150),无显著差异。结论认为,对载体角膜进行交联并未减少无菌性角膜溶解的发生率,也未提高装置保留率。
要点
- 68例受试者1:1随机接受CXL或non-CXL供体角膜载体。
- CXL组与non-CXL组装置取出时间无差异(P=.910)。
- 12个月保留率CXL组94% vs non-CXL组82%(P=.150),无显著差异。
核心结论
- 在计划接受BKPro植入且存在保留失败高风险的受试者中,载体角膜交联未减少无菌性角膜溶解的发生率,也未提高装置保留率。
研究设计与样本
- 前瞻性、双盲、随机、多中心临床试验,纳入68例计划接受BKPro植入的成人受试者,1:1随机分入CXL组或non-CXL组。
- 主要结局为从手术至BKPro取出的时间,次要终点为12个月保留率。
主要发现
- 手术时平均年龄62岁(范围24-89岁),42例(62%)为男性。
- 平均随访93周(范围6-201周),总体BKPro保留率为70%。
- 共20枚BKPro被取出,CXL组10枚、non-CXL组10枚,其中18枚因无菌性角膜溶解需取出。
- CXL组与non-CXL组装置取出时间无差异(P=.910)。
- 12个月保留率CXL组94% vs non-CXL组82%(P=.150),无显著差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess whether cross-linking the carrier donor cornea of the Boston Keratoprosthesis (BKPro) improves retention of the device in participants at high risk for keratolysis. DESIGN: Prospective, double-masked, randomized clinical trial. METHODS: In this multicenter study, 68 adult participants who were scheduled for BKPro implantation were enrolled. Masked participants were randomized to receive either a cross-linked (CXL) or non-cross-linked (non-CXL) donor corneal carrier. The Kaplan-Meier event-free survival was determined by the product-limit method and compared by the log-rank test to examine whether survival curves were different between the CXL and non-CXL groups. The primary outcome of the study was time from surgery to BKPro removal. The secondary endpoint was 12-month retention rate. RESULTS: A total of 68 participants were enrolled and randomized 1:1 to each group. The average age at the time of surgery was 62 (range = 24-89) years, and 42 participants (62%) were male. The overall BKPro retention rate was 70% during a mean follow-up time of 93 (range = 6-201) weeks. Twenty BKPros were removed, 10 in the CXL group and 10 in the non-CXL group, with 18 requiring removal because of sterile keratolysis. There was no difference in the time to removal between the groups during the study (P = .910). At 12 months, there was no significant difference in the retention rate in the CXL group (94%) vs the non-CXL group (82%, P = .150). CONCLUSIONS: In this prospective study, cross-linking of the carrier cornea prior to BKPro implantation did not reduce the incidence of sterile keratolysis or increase device retention among participants at high risk for retention failure.
引用
- De Arrigunaga S, Akpek EK, Aldave AJ, et al. Prospective, Randomized, Multicenter, Double-Masked, Clinical Trial of Corneal Cross-Linking for Boston Keratoprosthesis Carrier Tissue. Am J Ophthalmol. 2022. PMID: 36581190. doi:10.1016/j.ajo.2022.12.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。